Some good debate here, well most of it.
When you consider a company like PEB Pacific Edge with CX Bladder, a brilliant and proven test for Bladder Cancer, well ahead in the development of Plaxib and yet they are struggling to get traction. That's my biggest concern. Their market is far bigger than Plaxib.
Anyway I guess we will have a good idea by the end of this year.
Cap raises, fair dinkum, it's a BS argument compared to the marketability of a product.
- Forums
- ASX - By Stock
- KZA
- Extreme Chronic Undervalue
Extreme Chronic Undervalue, page-91
-
- There are more pages in this discussion • 138 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)